MoonLake Q3 cash $496M; positive Phase 2 data for sonelokimab in HS and PsA

MoonLake Immunotherapeutics

2023-Q3 EPS reported -$0.63

Cash & equivalents $496.0M at Sept 30, 2023, expected to fund Phase 3 programs and regulatory filings.
Positive full 24-week data from Phase 2 MIRA trial in hidradenitis suppurativa announced.
Landmark 12-week data from Phase 2 ARGO trial in psoriatic arthritis presented.
R&D expenses $7.6M in Q3 (down from $8.7M Q2); G&A expenses $5.4M (up from $4.5M).
Phase 3 initiation targeted for 2024; End of Phase 2 FDA meeting in December 2023; 24-week ARGO data expected Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MoonLake Immunotherapeutics reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

MoonLake Immunotherapeutics filing history →

Source: SEC EDGAR

accession 0001821586-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.